

April 30, 2018

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)
Contact: Ken Ishikawa
Executive officer in charge of administration
(TEL: 03-5777-8308)

Healios and Athersys Extend Negotiation Period to Expand MultiStem[®] Collaboration

As announced in the press release on March 13, 2018, “Healios and Athersys Announce Binding Letter of Intent to Expand MultiStem[®] Collaboration”, HEALIOS K.K. (“Healios”) entered into discussions to expand exclusive license and option rights regarding MultiStem, the proprietary technology of Athersys, Inc. (“Athersys”), by the end of April 2018.

Healios today announces that both Healios and Athersys have agreed to extend the negotiation period. Healios and Athersys will continue negotiations to conclude the expansion agreements.

If matters to be disclosed arise in the future, Healios will promptly make relevant announcements.